Sarcopenia in the Acute Stroke
Key facts
- Who runs it
- Centre Hospitalier Régional d'Orléans
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 6 people enrolled
- Started
- 28 Jun 2024
- Ended
- 6 Aug 2024
- Type of study
- Interventional
- Treatments tested
- Bioimpedancemetry
- Dynamometry
- Record updated
- 4 December 2025
- Why it stopped
- Departure of the principal investigator
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Acute stroke patient
- Over 18 years of age
- Functional Ambulation Categories (FAC) < 3
- NIHSS upper limb score ≥ 1
- Able to understand assessment instructions
- Non-objection to the study
- Affiliated with a social security scheme
Who cannot take part
- Person under guardianship or curatorship
- Person deprived of liberty
- Person under court protection
- Other neurological or rheumatological pathology limiting mobility
- Presence of a pacemaker or defibrillator
- Pregnant or breast-feeding woman
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Regardless of the cause of immobilization, within days or weeks there is rapidly a decrease in strength and muscle mass, which can lead to sarcopenia. In severe strokes, immobilization and neurologic damage may be added to promote sarcopenia. Several studies in Asian populations confirm rapid increases in sarcopenia rates after stroke, but there are only rare data in Western populations. The aim of this work is to monitor during the first 10 days after a severe stroke leading to a reduction in ambulation, the evolution of muscle strength (studied in dynamometry), body composition (studied by impedance measurement) and sarcopenia rates. Investigators will also look for factors that predict the occurrence of this sarcopenia (such as sex, age, initial deficiency, stroke volume, swallowing disorders, etc.).
The group in the trial
- Impedance measurement for acute stroke patientOther group
Acute stroke patients will benefit from impedance measurement and dynamometry to determine the evolution of sarcopenia rates.
Treatment: Bioimpedancemetry and Dynamometry
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Follow up of Strength and Body Composition With Impedancemeter Device During the First 10 Days After Acute Stroke.
- Record updated
- 4 December 2025